Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue 6, 2002, Pages 430-441

  Holst, Jens Juul ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Appetite; DPP IV; Exendin; glucagon; Incretin; Proglucagon

Indexed keywords

ANTIDIABETIC AGENT; ARGININE; DIPEPTIDYL PEPTIDASE IV; DPP 728; DRUG METABOLIZING ENZYME; ENZYME INHIBITOR; EXENDIN 4; FATTY ACID; GASTROINTESTINAL POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LITHIUM CHLORIDE; LY 307161 SR; PEPTIDE HORMONE; PLACEBO; PYRROLINE DERIVATIVE; RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; SOMATOSTATIN; SULFONYLUREA; UNCLASSIFIED DRUG;

APOPTOSIS; BODY WEIGHT; CELL MATURATION; CELL PROLIFERATION; CLINICAL STUDY; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GENE EXPRESSION; GLUCAGON RELEASE; GLUCOSE INTAKE; HEMOGLOBIN DETERMINATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; INTESTINE MUCOSA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SATIETY; SMALL INTESTINE; STEM CELL; UPPER GASTROINTESTINAL TRACT;

APPETITE REGULATION; DIABETES MELLITUS, TYPE 2; DIGESTIVE SYSTEM; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; INSULIN; ISLETS OF LANGERHANS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0036869408     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.328     Document Type: Review

References (141)

1. McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 1965; 25(10): 1317-1324.
2. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985; 28(8): 565-573.
3. Holst JJ, Orskov C. Incretin hormones -an update. Scand J Clin Lab Invest Suppl 2001; 61(5234): 75-85.
4. Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996; 31(7): 665-670.
5. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24-h secretion patterns. J Endocrinol 1993; 138(1): 159-166.
6. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2(8571): 1300-1304.
7. Nauck M, Schmidt WE, Ebert R, et al. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab 1989; 69(3): 654-662.
8. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76(4): 912-917.
9. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999; 96(26): 14843-14847.
10. Scrocchi LA, Brown TJ, MaClusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996; 2(11): 1254-1258.
11. Kolligs F, Fehmann HC, Goke R, Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995; 44(1): 16-19.
12. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat [see comments]. J Clin Invest 1995; 95(1): 417-421.
13. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose- dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 1996; 98(11): 2440-2445.
14. Edwards CM, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999; 48(1): 86-93.
15. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (noninsulin-dependent) diabetes. Diabetologia 1986; 29(1): 46-52.
16. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86(8): 3717-3723.
17. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50(3): 609-613.
18. Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB. Gut incretin hormones in identical twins discordant for noninsulin-dependent diabetes mellitus (NIDDM) -evidence for decreased glucagon- like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 1996; 135(4): 425-432.
19. Naslund E, Gryback P, Backman L, et al. Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998; 43(5): 945-952.
20. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996; 38(6): 916-919.
21. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91(1): 301-307.
22. Elahi D, McAloon Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994; 51(1): 63-74.
23. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type III diabetic patients. Diabetologia 2002; 58:1111-1119.
24. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983; 304(5924): 368-371.
25. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of posttranslational processing. J Biol Chem 1986; 261(25): 11880-11889.
26. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986; 119(4): 1467-1475.
27. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93(15): 7911-7916.
28. Hartmann B, Thulesen J, Hare KJ, et al. Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul Pept 2002; 105(3): 173-179.
29. Holst JJ. Glucagon-like Peptide 1(GLP-1): an intestinal hormone signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 1999; 10(6): 229-234.
30. Miholic J, Orskov C, Holst JJ, Kotzerke J, Meyer HJ. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 1991; 36(10): 1361-1370.
31. Toft-Nielsen M, Madsbad S, Holst JJ. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 1998; 41(10): 1180-1186.
32. Toft-Nielsen M, Madsbad S, Holst JJ. The effect of glucagon-like peptide-I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 1996; 45(5): 552-556.
33. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and 2 from isolated perfused porcine ileum. Am J Physiol 2000; 278(6): E1010-E1018.
34. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon- like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16(3): 390-410.
35. Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagon-like peptide-I (7-37) actions on endocrine pancreas. Diabetes 1989; 38(3): 338-342.
36. Thorens B. Expression cloning of the pancreatic beta-cell receptor for the gluco- incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89(18): 8641-8645.
37. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin- (9-39) an antagonist of the receptor. Diabetes 1993; 42(11): 1678-1682.
38. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon- like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16(3): 390-410.
39. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch 1998; 435(5): 583-594.
40. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361(6410): 362-365.
41. Gromada J, Dissing S, Bokvist K, et al. Glucagon-like peptide-I increases cytoplasmic calcium in insulin- secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes 1995; 44(7): 767-774.
42. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361(6410): 362-365.
43. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch 1998; 435(5): 583-594.
44. Gutniak MK, Juntti-Berggren L, Hellstrom PM, Guenifi A, Holst JJ, Efendic S. Glucagon-like peptide-I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 1996; 19(8): 857-863.
45. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 1995; 32(1): 13-16.
46. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130(1): 159-166.
47. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells [In Process Citation]. Diabetologia 1999; 42(7): 856-864.
48. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48(12): 2270-2276.
49. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49(5): 741-748.
50. Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999; 48(12): 2358-2366.
51. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic- duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141(12): 4600-4605.
52. Bregenholt S, Moldrup A, Blume N, Knudsen LB, Petersen JS. The GLP-1 analogue, NN2211, inhibits free fatty acid induced apoptosis in primary rat beta cells. Diabetologia 2001; 44(Suppl. 1): A19.
53. Bregenholt S, Moldrup A, Knudsen LB, Petersen JS. The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat beta cells. Diabetes 2001; 50(Suppl. 2): A31.
54. Bonner-Weir S. Life and death of the pancreatic beta cells. Trends Endocrinol Metab 2000; 11 (9): 375-378.
55. Sturis J, Jappe MB, Knudsen LB, et al. Long-acting GLP-1 derivative NN2211 markedly attenuates diabetes development in the male Zucker fatty rat. Diabetologia 2000; 43(Suppl. 1): A145.
56. Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998; 47(3): 358-364.
57. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988; 123(4): 2009-2013.
58. Orskov C, Poulsen SS. Glucagon-like peptide-I-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes 1991; 40(10): 1292-1296.
59. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide-I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 1997; 46(5): 785-791.
60. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87(3): 1239-1246.
61. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide-I(7-36) amide in type I diabetic patients. Diabetes Care 1996; 19(6): 580-586.
62. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 1994; 43(1): 104-108.
63. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38(4): 665-673.
64. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273(5 Pt 1): E981-E988.
65. Holst JJ. Enteroglucagon. Annu Rev Physiol 1997; 59: 257-271.
66. Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995; 40(5): 1074-1082.
67. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38(4): 665-673.
68. Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995; 40(5): 1074-1082.
69. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Örskov C, Schmeigel WH. Inhibition of gastric emptying by physiological and pharmalogical doses of exogenous glucagon-like peptide-1 (GLP-1) outweighs insulinotropic effects in healthy normoglycemic volunteers. Am J Physiol 1997; 273: E981-E988.
70. Wettergren A, Wojdemann M, Meisner S, Stadil F, Hoist JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997; 40(5): 597-601.
71. Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide-1 7-36 amide and peptide YY from the L- cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 1994; 29(6): 501-505.
72. Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide-I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide-I. Diabetes 1996; 45(6): 832-835.
73. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent- mediated central mechanisms. Am J Physiol 1997; 273(4 Pt 1): G920-G927.
74. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996; 271(5 Pt 1): E808-E813.
75. Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275(5 Pt 1): G984-G992.
76. Young A, Denaro M. Roles of amylin in diabetes and in regulation of nutrient load [editorial]. Nutrition 1998; 14(6): 524-527.
77. Read N, French S, Cunningham K. The role of the gut in regulation food intake in man. Nutr Rev 1994; 52(1): 1-10.
78. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101 (3): 515-520.
79. Gutzwiller JP, Ke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44(1): 81-86.
80. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obestet Relat Metab Disord 1999; 23(3): 304-311.
81. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276(5 Pt 2): R1541-R1544.
82. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86(9): 4382-4389.
83. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding [see comments]. Nature 1996; 379(6560): 69-72.
84. Tang-Christensen M, Larsen PJ, Goke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271(4 Pt 2): R848-R856.
85. Thiele TE, van Dijk G, Campfield LA, et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol 1997; 272 (2 Pt 2): R726-R730.
86. Bloom SR. Glucagon-like peptide-1 and satiety: reply. Nature 1997; 385:214.
87. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7(11): 2294-2300.
88. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 1998; 47(4): 530-537.
89. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997; 138(10): 4445-4455.
90. McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol 1998; 274(1 Pt 2): R23-R29.
91. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997; 77(1): 257-270.
92. Rinaman L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol 1999; 277(2 Pt 2): R582-R590.
93. Rinaman L. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am J Physiol 1999; 277(5 Pt 2): R1537-R1540.
94. Valverde I, Morales M, Clemente F, et al. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 1994; 349(2): 313-316.
95. Morales M, Lopez-Delgado MI, Alcantara A, et al. Preserved GLP-I effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 1997; 48(8): 1264-1269.
96. Yang H, Egan JM, Wang Y, et al. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol 1998; 275(3 Pt 1): C675-C683.
97. Toft-Nielsen M, Madsbad S, Holst JJ. The effect of glucagon-like peptide-I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 1996; 45(5): 552-556.
98. Orskov L, Holst JJ, Moller J, et al. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 1996; 39(10): 1227-1232.
99. Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997; 160(4): 413-422.
100. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82(2): 473-478.
101. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 2000; 49(4): 611-617.
102. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagon-like peptide-1 7-36 amide and glucagon-like peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993; 42(5): 658-661.
103. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide-I(7-36) amide in type I diabetic patients. Diabetes Care 1996; 19(6): 580-586.
104. Idris I, Patiag D, Gray S, Donnelly R. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochem Pharmacol 2002; 63(5): 993-996.
105. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus [see comments]. N Engl J Med 1992; 326(20): 1316-1322.
106. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic action of glucagon-like peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992; 15(2): 270-276.
107. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon- like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 1993; 36(8): 741-744.
108. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998; 21(11): 1925-1931.
109. Nauck MA, Holst JJ, Willms B. Glucagon-like peptide 1 and its potential in the treatment of noninsulin-dependent diabetes mellitus. Horm Metab Res 1997; 29(9): 411-416.
110. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 2001; 86(8): 3853-3860.
111. Rachman J, Barrow BA, Levy JC, Turner RC. Nearnormalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997; 40(2): 205-211.
112. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001; 24(8): 1416-1421.
113. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP- 1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39(12): 1546-1553.
114. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide-I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44(9): 1126-1131.
115. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80(3): 952-957.
116. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996; 318(2-3): 429-435.
117. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L-cells of the porcine intestine. Endocrinology 1999; 140(11): 5356-5363; In Process Citation.
118. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent- mediated central mechanisms. Am J Physiol 1997; 273(4 Pt 1): G920-G927.
119. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima. A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996; 271(5 Pt 1): E808-E813.
120. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 2000; 279(4): R1449-R1454.
121. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin- (9-39) an antagonist of the receptor. Diabetes 1993; 42(11): 1678-1682.
122. Knudsen LB, Agersø H, Bjenning C, et al. GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes. Drugs Future 2001; 26: 677-685.
123. Mentlein R, Dipeptidyl-peptidase IV. (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85(1): 9-24.
124. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 that have extended metabolic stability and improved biological activity. Diabetologia 1998; 41(3): 271-278.
125. Greig NH, Holloway HW, De Ore K, et al. Once-daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999; 42(1): 45-50.
126. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48(5): 1026-1034.
127. Szayna M, Doyle ME, Betkey JA, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141(6): 1936-1941.
128. Fineman M, Bicsak T, Shen L, et al. AC2993 (Synthetic extendin-4) added to existing metformin (MET) and/or sulfonyluera (SFU) treatment improved glycemic control in patients with type 2 diabetes (DM2) during 28 days of treatment. Diabetes 2002; 51(Suppl. 2): A85.
129. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51(2): 424-429.
130. Lawrence B, Wen SY, Jette L, Thibaudeau K, Castilla C. CJC-1131, the novel long-acting GLP-1 analogue, delays gastric emptying and demonstrates safety and tolerability in preclinical testing. Diabetes 2002; 51(Suppl. 2): A84.
131. Kapitza C, Trautmann M, Heise T, Heinemann L, Patterson B. Daily administration of LY307161 SR (GLP-1 analog) normalizes blood glucose in type 2 diabetes. Diabetes 2002; 51(Suppl. 2): A84.
132. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47(11): 1663-1670.
133. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996; 271(3 Pt 1): E458-E464.
134. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998; 47(5): 764-769.
135. Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000; 404(1-2): 239-245.
136. Pospisilik JA, Stafford SG, Demuth HU, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002; 51(4): 943-950.
137. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25(5): 869-875.
138. Pederson RA, Kieffer TJ, Pauly R, Kofod H, Kwong J, McIntosh CH. The entero-insular axis in dipeptidyl peptidase IV-negative rats. Metabolism 1996; 45(11): 1335-1341.
139. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97(12): 6874-6879.
140. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22(7): 1137-1143.
141. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359(9309): 824-830.